CD8A and neoplasm: Consistent with the results of CD8+ T cell depletion, tumor progression was re-established in 70–80% of mice with a CD8−/− background implanted with either GL261-FGL2KO or LLC-FGL2KO tumor cells (Fig. 3e–g).